A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916 on ClinicalTrials.gov · last registry update 2026-06-04
Finished 21 November 2025, after enrolling 376 people. Primary outcome, as filed: Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 376
- Started
- 2024-09-13
- Primary completion
- 2025-11-21 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.